{
    "qwen-v2.5-14b-instruct": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "qwen-v2.5-14b-instruct",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib",
                "Nilotinib",
                "Bosutinib",
                "Ponatinib",
                "Chlorambucil",
                "Cyclophosphamide",
                "Fludarabine",
                "Ibrutinib",
                "Venetoclax",
                "Alemtuzumab",
                "Ofatumumab",
                "Rituximab",
                "Blinatumomab",
                "Inotuzumab ozogamicin",
                "Midostaurin",
                "Clofarabine",
                "Cladribine",
                "Eltrombopag",
                "Elotuzumab",
                "Daratumumab",
                "Idecabtagene vicleucel",
                "Pembrolizumab"
            ]
        }
    ],
    "phi-v4": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "phi-v4",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Bosutinib (Bosulif)",
                "Ponatinib (Iclusig)",
                "Nucleoside analogs (Cytarabine, Ara-C)",
                "Fludarabine (Fludara)",
                "Cladribine (Leustatin)",
                "Gemtuzumab ozogamicin (Mylotarg)",
                "Decitabine (Dacogen)",
                "Vincristine (Oncovin)",
                "Daunorubicin (Cerubidine)",
                "Doxorubicin (Adriamycin, Doxil)",
                "Idarubicin (Idamycin)",
                "Cytarabine (Ara-C)",
                "Etoposide (VP-16, VePesid)",
                "Bleomycin (Blenoxane)",
                "Methotrexate",
                "Mercaptopurine (6-MP)",
                "6-Thioguanine (6-TG)",
                "Cytarabine liposome (Depocyt)",
                "Carmustine (BCNU, BiCNU)",
                "Temozolomide (Temodar)",
                "L-asparaginase (Elspar, L-Asparaginase)"
            ]
        }
    ],
    "mistral-small-instruct-24B": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "mistral-small-instruct-24B",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Bosutinib (Bosulif)",
                "Ponatinib (Iclusig)",
                "Ruxolitinib (Jakafi)",
                "Vosaroxin (Vyxeos)",
                "Cytarabine (Ara-C)",
                "Daunorubicin (Cerubidine)",
                "Idarubicin (Idamycin)",
                "Cladribine (Leustatin)",
                "Fludarabine (Fludara)",
                "Ofatumumab (Arzerra)",
                "Oblimersen (Genasense)",
                "Blinatumomab (Blincyto)",
                "Inotuzumab ozogamicin (Besponsa)",
                "Venetoclax (Venclexta)",
                "Ibrutinib (Imbruvica)",
                "Idelalisib (Zydelig)",
                "Midostaurin (Rydapt)",
                "Gilteritinib (Xospata)",
                "Enasidenib (Idhifa)",
                "Givosiran (Givlaari)",
                "Rituximab (Rituxan)"
            ]
        }
    ],
    "gemma-3": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "gemma-3",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Bosutinib (Bosulif)",
                "Ponatinib (Iclusig)",
                "Venetoclax (Venclexta)",
                "Fludarabine",
                "Cytarabine (Ara-C)",
                "Daunorubicin",
                "Doxorubicin",
                "Idarubicin",
                "Gemtuzumab ozogamicin (Mylotarg)",
                "Blinatumomab (Blincyto)",
                "Inotuzumab ozogamicin (Besponsa)",
                "Tisagenlecleucel (Kymriah)",
                "Axicabtagene ciloleucel (Yescarta)",
                "Lisocabtagene maraleucel (Breyanzi)",
                "Brexucabtagene autoleucel (Tecartus)",
                "Decitabine",
                "Azacitidine",
                "Clofarabine",
                "Omacetaxine mepesuccinate (Synribo)",
                "Nelarabine",
                "Vorinostat"
            ]
        }
    ],
    "gpt-4o": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "gpt-4o",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Bosutinib (Bosulif)",
                "Ponatinib (Iclusig)",
                "Ibrutinib (Imbruvica)",
                "Acalabrutinib (Calquence)",
                "Venetoclax (Venclexta)",
                "Idelalisib (Zydelig)",
                "Duvelisib (Copiktra)",
                "Fludarabine (Fludara)",
                "Cladribine (Leustatin)",
                "Bendamustine (Treanda)",
                "Rituximab (Rituxan)",
                "Obinutuzumab (Gazyva)",
                "Ofatumumab (Arzerra)",
                "Blinatumomab (Blincyto)",
                "Inotuzumab ozogamicin (Besponsa)",
                "Gemtuzumab ozogamicin (Mylotarg)",
                "Midostaurin (Rydapt)",
                "Enasidenib (Idhifa)",
                "Ivosidenib (Tibsovo)",
                "Asparaginase Erwinia chrysanthemi (Erwinaze)",
                "Pegaspargase (Oncaspar)"
            ]
        }
    ],
    "gpt-4o-mini": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "gpt-4o-mini",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Bosutinib (Bosulif)",
                "Ponatinib (Iclusig)",
                "Etoposide (VePesid)",
                "Cytarabine (Cytosar-U)",
                "Daunorubicin (Cerubidine)",
                "Vincristine (Oncovin)",
                "Hydroxyurea (Hydrea)",
                "L-asparaginase (Elspar)",
                "Ruxolitinib (Jakafi)",
                "Inotuzumab ozogamicin (Besponsa)",
                "Blincyto (Blinatumomab)",
                "Clofarabine (Clolar)",
                "Mecasermin (Increlex)",
                "Acalabrutinib (Calquence)",
                "Venetoclax (Venclexta)",
                "Midostaurin (Rydapt)",
                "Gemtuzumab ozogamicin (Mylotarg)",
                "Tisagenlecleucel (Kymriah)",
                "Lisocabtagene maraleucel (Breyanzi)",
                "Selinexor (Xpovio)",
                "Elranatamab (Elrexfio)"
            ]
        }
    ],
    "gpt-4-32k": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "gpt-4-32k",
            "response": [
                "Gleevec (Imatinib)",
                "Tasigna (Nilotinib)",
                "Sprycel (Dasatinib)",
                "Iclusig (Ponatinib)",
                "Bosulif (Bosutinib)",
                "Rydapt (Midostaurin)",
                "Venclexta (Venetoclax)",
                "Blincyto (Blinatumomab)",
                "Besponsa (Inotuzumab Ozogamicin)",
                "Mylotarg (Gemtuzumab Ozogamicin)",
                "Rituxan (Rituximab)",
                "Arzerra (Ofatumumab)",
                "Gazyva (Obinutuzumab)",
                "Calquence (Acalabrutinib)",
                "Imbruvica (Ibrutinib)",
                "Zydelig (Idelalisib)",
                "Copiktra (Duvelisib)",
                "Vitrakvi (Larotrectinib)",
                "Rozlytrek (Entrectinib)",
                "Xospata (Gilteritinib)",
                "Idhifa (Enasidenib)",
                "Tibsovo (Ivosidenib)",
                "Daurismo (Glasdegib)",
                "Rydapt (Midostaurin)"
            ]
        }
    ],
    "gpt-35-turbo-16k": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "gpt-35-turbo-16k",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Ponatinib (Iclusig)",
                "Bosutinib (Bosulif)",
                "Venetoclax (Venclexta)",
                "Midostaurin (Rydapt)",
                "Ruxolitinib (Jakafi)",
                "Idelalisib (Zydelig)",
                "Arsenic trioxide (Trisenox)",
                "Tretinoin (Vesanoid)",
                "Decitabine (Dacogen)",
                "Azacitidine (Vidaza)",
                "Clofarabine (Clolar)",
                "Fludarabine (Fludara)",
                "Cytarabine (Cytosar-U)",
                "Mercaptopurine (Purinethol)",
                "Vincristine (Oncovin)",
                "Doxorubicin (Adriamycin)",
                "Daunorubicin (Cerubidine)",
                "Etoposide (VP-16)",
                "Mitoxantrone (Novantrone)",
                "Cladribine (Leustatin)",
                "Hydroxyurea (Hydrea)"
            ]
        }
    ],
    "o1-mini": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "o1-mini",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Bosutinib (Bosulif)",
                "Ponatinib (Iclusig)",
                "Venetoclax (Venclexta)",
                "Ruxolitinib (Jakafi)",
                "Midostaurin (Rydapt)",
                "Gilteritinib (Xospata)",
                "Ivosidenib (Tibsovo)",
                "Enasidenib (Idhifa)",
                "Decitabine (Dacogen)",
                "Azacitidine (Vidaza)",
                "Fludarabine (Fludara)",
                "Clofarabine (Clolar)",
                "Cytarabine (Ara-C)",
                "Methotrexate",
                "Daunorubicin",
                "Mercaptopurine (6-MP)",
                "Thioguanine",
                "Blinatumomab (Blincyto)",
                "Nelarabine (Arranon)",
                "Talacotuzumab",
                "Lenalidomide (Revlimid)"
            ]
        }
    ],
    "anthropic.claude-3-5-sonnet-v1:0": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "anthropic.claude-3-5-sonnet-v1:0",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Ponatinib (Iclusig)",
                "Venetoclax (Venclexta)",
                "Rituximab (Rituxan)",
                "Obinutuzumab (Gazyva)",
                "Ibrutinib (Imbruvica)",
                "Acalabrutinib (Calquence)",
                "Idelalisib (Zydelig)",
                "Blinatumomab (Blincyto)",
                "Inotuzumab ozogamicin (Besponsa)",
                "Midostaurin (Rydapt)",
                "Gilteritinib (Xospata)",
                "Cytarabine (Cytosar-U)",
                "Daunorubicin (Cerubidine)",
                "Vincristine (Oncovin)",
                "Arsenic trioxide (Trisenox)",
                "All-trans retinoic acid (ATRA, Vesanoid)",
                "Fludarabine (Fludara)",
                "Cladribine (Leustatin)",
                "Azacitidine (Vidaza)",
                "Decitabine (Dacogen)",
                "Ruxolitinib (Jakafi)"
            ]
        }
    ],
    "anthropic.claude-3-opus-v1:0": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "anthropic.claude-3-opus-v1:0",
            "response": [
                "Imatinib (Gleevec)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Bosutinib (Bosulif)",
                "Ponatinib (Iclusig)",
                "Asparaginase Erwinia chrysanthemi (Erwinaze)",
                "Cyclophosphamide",
                "Cytarabine (Ara-C)",
                "Daunorubicin (Cerubidine)",
                "Doxorubicin (Adriamycin)",
                "Etoposide (VP-16)",
                "Vincristine (Oncovin)",
                "Pegaspargase (Oncaspar)",
                "Methotrexate",
                "Mercaptopurine (6-MP)",
                "Thioguanine (6-TG)",
                "Nelarabine (Arranon)",
                "Clofarabine (Clolar)",
                "Fludarabine (Fludara)",
                "Pentostatin (Nipent)",
                "Rituximab (Rituxan)",
                "Alemtuzumab (Campath)",
                "Ofatumumab (Arzerra)",
                "Blinatumomab (Blincyto)"
            ]
        }
    ],
    "anthropic.claude-3-sonnet-v1:0": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "anthropic.claude-3-sonnet-v1:0",
            "response": [
                "Imatinib (BCR-ABL tyrosine kinase inhibitor, STI571)",
                "Dasatinib (BMS-354825)",
                "Nilotinib (AMN107)",
                "Ponatinib (AP24534)",
                "Bosutinib (SKI-606)",
                "Asciminib (ABL001)",
                "Venetoclax (ABT-199)",
                "Glasdegib (PF-04449913)",
                "Gilteritinib (ASP2215)",
                "Midostaurin (PKC412)",
                "Ruxolitinib (INCB018424)",
                "Fedratinib (SAR302503)",
                "Crenolanib (CP-868596)",
                "Quizartinib (AC220)",
                "Gemtuzumab ozogamicin (Mylotarg)",
                "Inotuzumab ozogamicin (CMC-544)",
                "Blinatumomab (MT103)",
                "Rituximab (Rituxan)",
                "Obinutuzumab (GA101)",
                "Alemtuzumab (Campath)",
                "Clofarabine (Clohare)",
                "Nelarabine (Arranon)",
                "Cladribine (Leustatin)",
                "Vincristine (Oncovin)"
            ]
        }
    ],
    "anthropic.claude-3-haiku-v1:0": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "anthropic.claude-3-haiku-v1:0",
            "response": [
                "Imatinib (IMT)",
                "Dasatinib (DST)",
                "Nilotinib (NLT)",
                "Bosutinib (BST)",
                "Ponatinib (PNT)",
                "Venetoclax (VNT)",
                "Midostaurin (MDS)",
                "Gilteritinib (GIT)",
                "Acalabrutinib (ACB)",
                "Ibrutinib (IBR)",
                "Idelalisib (IDL)",
                "Blinatumomab (BLN)",
                "Gemtuzumab ozogamicin (GZO)",
                "Inotuzumab ozogamicin (IOZ)",
                "Asparaginase (ASP)",
                "Clofarabine (CLF)",
                "Fludarabine (FLU)",
                "Cytarabine (CYT)",
                "Daunorubicin (DNR)",
                "Doxorubicin (DOX)",
                "Etoposide (ETP)",
                "Methotrexate (MTX)",
                "Mercaptopurine (MCP)",
                "Thioguanine (THG)"
            ]
        }
    ],
    "meta.llama3-8b-instruct-v1:0": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "meta.llama3-8b-instruct-v1:0",
            "response": [
                "Hydroxyurea (Hydrea)",
                "Mercaptopurine (Purinethol)",
                "Cytarabine (Cytosar-U)",
                "Daunorubicin (Daunomycin)",
                "Mitoxantrone (Novantrone)",
                "Vincristine (Oncovin)",
                "Asparaginase (Elspar)",
                "Idarubicin (Idamycin)",
                "Cladribine (Leustatin)",
                "Fludarabine (Fludara)",
                "Gemtuzumab ozogamicin (Mylotarg)",
                "Topotecan (Hycamtin)",
                "Etoposide (Etopophos)",
                "Caspofungin (Cancidas)",
                "Clofarabine (Clolar)",
                "Pegaspargase (Oncaspar)",
                "Mitoxantrone (Novantrone)",
                "Ibritumomab tiuxetan (Zevalin)",
                "Blinatumomab (Blincyto)",
                "Inotuzumab ozogamicin (Besponsa)",
                "Vosaroxin (Visomitin)",
                "Isturisa (Pomalidomide)",
                "Venetoclax (Venclexta)",
                "Luspatercept (Reblozyl)",
                "Gilteritinib (XOSPATA)",
                "Ibrutinib (Imbruvica)",
                "Axicabtagene ciloleucel (Yescarta)",
                "Tisagenlecleucel (Kymriah)"
            ]
        }
    ],
    "meta.llama3-70b-instruct-v1:0": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "meta.llama3-70b-instruct-v1:0",
            "response": [
                "Mercaptopurine (Purinethol)",
                "Rituximab (Rituxan)",
                "Dasatinib (Sprycel)",
                "Nilotinib (Tasigna)",
                "Imatinib (Gleevec)",
                "Bosutinib (Bosulif)",
                "Omacetaxine (Synribo)",
                "Cladribine (Leustatin)",
                "Fludarabine (Fludara)",
                "Arabinoside cytosine (Cytosar-U)",
                "Idarubicin (Idamycin)",
                "Mitoxantrone (Novantrone)",
                "Teniposide (Vumon)",
                "Vinblastine (Velban)",
                "Vincristine (Oncovin)",
                "Prednisone (Deltasone)",
                "Cyclophosphamide (Cytoxan)",
                "Doxorubicin (Adriamycin)",
                "Vidarabine (Vira-A)",
                "Asparaginase (Elspar)",
                " Nelarabine (Arranon)",
                " Clofarabine (Clolar)",
                "Decitabine (Dacogen)",
                "Midostaurin (Rydapt)",
                "Enasidenib (Idhifa)"
            ]
        }
    ],
    "amazon.titan-text-express-v1": [
        {
            "call": "limited-list-referents",
            "context": {
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for leukemia"
            },
            "model": "amazon.titan-text-express-v1",
            "response": "[\n  {\n    \"referent\": \"Amsacrine\",\n    \"abbrev\": \"AMS\"\n  },\n  {\n    \"referent\": \"Arsenic trioxide\",\n    \"abbrev\": \"ATO\"\n  },\n  {\n    \"referent\": \"Asparaginase\",\n    \"abbrev\": \"ASP\"\n  },\n  {\n    \"referent\": \"Auranofin\",\n    \"abbrev\": \"AUR\"\n  },\n  {\n    \"referent\": \"Azacitidine\",\n    \"abbrev\": \"AZA\"\n  },\n  {\n    \"referent\": \"Bevacizumab\",\n    \"abbrev\": \"BVZ\"\n  },\n  {\n    \"referent\": \"Bendamustine\",\n    \"abbrev\": \"BEN\"\n  },\n  {\n    \"referent\": \"Bortezomib\",\n    \"abbrev\": \"BTZ\"\n  },\n  {\n    \"referent\": \"Busulfan\",\n    \"abbrev\": \"BUS\"\n  },\n  {\n    \"referent\": \"Carboplatin\",\n    \"abbrev\": \"CBP\"\n  },\n  {\n    \"referent\": \"Chlorambucil\",\n  },\n  {\n    \"referent\": \"Clofarabine\",\n  },\n  {\n    \"referent\": \"Cytarabine\",\n  },\n  {\n    \"referent\": \"Daunorubicin\",\n  },\n  {\n    \"referent\": \"Doxorubicin\",\n  },\n  {\n    \"referent\": \"Etoposide\",\n  },\n  {\n    \"referent\": \"Fludarabine\",\n  },\n  {\n    \"referent\": \"Idarubicin\",\n  },\n  {\n    \"referent\": \"Imatinib\",\n  },\n  {\n    \"referent\": \"Interferon alpha\",\n  },\n  {\n    \"referent\": \"Irinotecan\",\n  },\n  {\n    \"referent\": \"Lomustine\",\n  },\n  {\n    \"referent\": \"Mitoxantrone\",\n  },\n  {\n    \"referent\": \"Mitomycin C\",\n  },\n  {\n    \"referent\": \"Nitrosoureas\",\n  },\n  {\n    \"referent\": \"Pegaspargase\",\n  },\n  {\n    \"referent\": \"Pralatrexate\",\n  },\n  {\n    \"referent\": \"Rituximab\",\n  },\n  {\n    \"referent\": \"Thalidomide\",\n  },\n  {\n    \"referent\": \"Tretinoin\",\n  }\n]"
        }
    ]
}